Xu H - Search Results

1

NEAT1 promotes the malignant development of bladder cancer by regulating the miR-101/VEGF-C pathway in vitro and in vivo.

Zhang H, Yu S, Fei K, Huang Z, Deng S, Xu H. Zhang H, et al. Among authors: xu h. BMC Urol. 2022 Nov 25;22(1):193. doi: 10.1186/s12894-022-01151-z. BMC Urol. 2022. PMID: 36434587 Free PMC article.

2

Targeting EGFL7 expression through RNA interference suppresses renal cell carcinoma growth by inhibiting angiogenesis.

Xu HF, Chen L, Liu XD, Zhan YH, Zhang HH, Li Q, Wu B. Xu HF, et al. Asian Pac J Cancer Prev. 2014;15(7):3045-50. doi: 10.7314/apjcp.2014.15.7.3045. Asian Pac J Cancer Prev. 2014. PMID: 24815445 Free article.

3

Prognostic role of microRNA-100 in patients with bladder cancer.

Cao YH, Zhang HH, Xu HF, Duan YJ, Li Q, Huang B. Cao YH, et al. Among authors: xu hf. Genet Mol Res. 2015 Dec 7;14(4):15948-54. doi: 10.4238/2015.December.7.6. Genet Mol Res. 2015. PMID: 26662386 Free article.

4

Role of 5-Aza-CdR in mitomycin-C chemosensitivity of T24 bladder cancer cells.

Zhang HH, Huang B, Cao YH, Li Q, Xu HF. Zhang HH, et al. Oncol Lett. 2017 Nov;14(5):5652-5656. doi: 10.3892/ol.2017.6853. Epub 2017 Aug 31. Oncol Lett. 2017. PMID: 29142609 Free PMC article.

5

The safety and efficiency of a 1470 nm laser in obtaining tract hemostasis in tubeless percutaneous nephrolithotomy: a retrospective cross-sectional study.

Zhang H, Xu H, Fei K, Guo D, Duan Y. Zhang H, et al. Among authors: xu h. BMC Urol. 2022 Jul 2;22(1):94. doi: 10.1186/s12894-022-01046-z. BMC Urol. 2022. PMID: 35780099 Free PMC article.

6

Nomogram to predict the risk of adverse outcomes in patients with residual stones following percutaneous nephrolithotomy.

Xie F, Deng S, Fei K, Xu H, Zhang H. Xie F, et al. Among authors: xu h. Int Braz J Urol. 2023 Sep-Oct;49(5):599-607. doi: 10.1590/S1677-5538.IBJU.2023.0111. Int Braz J Urol. 2023. PMID: 37390125 Free PMC article.

7

Reply to Editorial Comment on "The Association Between Stone Heterogenicity and the Success of Shock Wave Lithotripsy for High Density Upper Urinary Tract Stones".

Xu H, Bai S. Xu H, et al. Urology. 2024 Nov 19:S0090-4295(24)01077-X. doi: 10.1016/j.urology.2024.11.026. Online ahead of print. Urology. 2024. PMID: 39571618 No abstract available.

8

The Association Between Stone Heterogenicity and the Success of Shock Wave Lithotripsy for High Density Upper Urinary Tract Stones: A Muti-Center Prospective Cohort.

Xu H, Liu J, Li Z, Ge C, Guo H, Song S, Li Z, Bai S. Xu H, et al. Urology. 2024 Nov 20:S0090-4295(24)00970-1. doi: 10.1016/j.urology.2024.10.069. Online ahead of print. Urology. 2024. PMID: 39577810

9

Serum ACSL4 levels in prostate cancer patients and its relationship between patient prognosis: A prospective observational study.

Wang H, Xu H, Yang Y. Wang H, et al. Among authors: xu h. Medicine (Baltimore). 2024 Oct 4;103(40):e39119. doi: 10.1097/MD.0000000000039119. Medicine (Baltimore). 2024. PMID: 39465761 Free PMC article.

10

Nomogram for the Pathological Complete Response After Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Patients.

Shan L, Xu H, Piao C, Liu Z, Xie S. Shan L, et al. Among authors: xu h. Ann Surg Oncol. 2025 Jan;32(1):589-597. doi: 10.1245/s10434-024-16429-9. Epub 2024 Oct 28. Ann Surg Oncol. 2025. PMID: 39467974

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

45,845 results

Search Page

Filters